Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana

The FDA approved the drug, a member of the SGLT2 class, to reduce the risk of major heart problems—including heart attack, stroke and cardiovascular death—in high-risk Type 2 patients. And as the New Jersey drugmaker was quick to point out, Invokana is n https://www.fiercepharma.com/marketing/j-j-bags-long-awaited-cardiovascular-nod-for-diabetes-med-invokana